Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Kalvista Pharmaceuticals Inc (KALV)
Kalvista Pharmaceuticals Inc (KALV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 222,440
  • Shares Outstanding, K 34,169
  • Annual Sales, $ 0 K
  • Annual Income, $ -82,340 K
  • 60-Month Beta 1.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.20
Trade KALV with:

Options Overview Details

View History
  • Implied Volatility 73.96% ( +73.96%)
  • Historical Volatility 63.77%
  • IV Percentile 14%
  • IV Rank 17.86%
  • IV High 253.26% on 11/18/22
  • IV Low 34.99% on 07/18/22
  • Put/Call Vol Ratio 0.00
  • Today's Volume 0
  • Volume Avg (30-Day) 26
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 218
  • Open Int (30-Day) 928

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 04/30/23
See More
  • Average Estimate -0.92
  • Number of Estimates 4
  • High Estimate -0.68
  • Low Estimate -1.29
  • Prior Year -0.98
  • Growth Rate Est. (year over year) +6.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.26 +5.12%
on 03/22/23
8.31 -20.88%
on 03/03/23
-0.75 (-10.18%)
since 02/27/23
3-Month
5.87 +12.01%
on 12/28/22
8.54 -23.01%
on 02/08/23
+0.69 (+11.82%)
since 12/27/22
52-Week
4.12 +59.59%
on 10/20/22
17.06 -61.46%
on 09/02/22
-9.45 (-58.96%)
since 03/25/22

Most Recent Stories

More News
KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

KalVista Pharmaceuticals, Inc. (KALV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions...

KALV : 6.59 (+1.23%)
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided...

KALV : 6.59 (+1.23%)
Wall Street Analysts See a 155.32% Upside in KalVista Pharmaceuticals, Inc. (KALV): Can the Stock Really Move This High?

The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 155.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

KALV : 6.59 (+1.23%)
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented...

KALV : 6.59 (+1.23%)
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced...

KALV : 6.59 (+1.23%)
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development

KalVista Pharmaceuticals, Inc . (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided...

KALV : 6.59 (+1.23%)
KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced...

KALV : 6.59 (+1.23%)
What Makes KalVista Pharmaceuticals, Inc. (KALV) a New Buy Stock

KalVista Pharmaceuticals, Inc. (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

KALV : 6.59 (+1.23%)
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 149.94%: Read This Before Placing a Bet

The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 149.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...

KALV : 6.59 (+1.23%)
KalVista Pharmaceuticals Presents Data at Western Society of Allergy, Asthma & Immunology (WSAAI) 60th Annual Scientific Session

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented...

KALV : 6.59 (+1.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which...

See More

Key Turning Points

3rd Resistance Point 6.92
2nd Resistance Point 6.75
1st Resistance Point 6.63
Last Price 6.59
1st Support Level 6.34
2nd Support Level 6.17
3rd Support Level 6.05

See More

52-Week High 17.06
Fibonacci 61.8% 12.12
Fibonacci 50% 10.59
Fibonacci 38.2% 9.06
Last Price 6.59
52-Week Low 4.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar